Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
AVAX Technologies Inc. Stock Analysis AVXT
United States Health Care Nano Cap AVAX Technologies, Inc. is an immuno-oncology company, which engages in the provision of development and commercialization of vaccine therapies and technologies for the treatment of cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 29 full-time employees. The firm is focused on developing and commercializing its Autologous Cell (AC) Vaccine Technology Platform for the treatment of cancer. The AC Vaccine is a platform technology, which allows a patient's immune system to recognize its own cancer cells as foreign through the process of haptenization, cell processing and regimen of administration. The firm has approximately two vaccines that have completed Phase II clinical trials, both designated with Orphan Drug Status. MVAX is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage IV melanoma patients with measurable metastasis. OVAX is the Company's post-surgical autologous cell vaccine for Stage III and IV ovarian cancer. The OVAX trial is a Phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients.
Read More AVAX Technologies Inc (AVXT) Chart
Key Statistics of AVAX Technologies Inc (AVXT)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
50.89KP/E Ratio (TTM)
-Market Cap
6894.30Avg. Volume
22.63KDividend Yield
-Financial Metrics & Statements of AVAX Technologies Inc (AVXT)
FAQ's for AVAX Technologies Inc (AVXT)
- According to Musaffa’s Shariah screening methodology, AVAX Technologies Inc (AVXT) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes AVAX Technologies Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in AVAX Technologies Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of AVAX Technologies Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of AVAX Technologies Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of AVAX Technologies Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.